Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026 ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to Phase 1b dose optimization Dosing of first patient with ARR-002, a dual-targeting MUC16/NaPi2b
Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026 IND clearance of ARR-002, ArriVent’s dual-targeting MUC16/NaPi2b tetravalent ADC, advances into the clinic and plans to dose its first patient in 2H 2026, initially for ovarian
Superior efficacy and favorable tolerability in animal models support the potential of ARR-002 to overcome limitations of single-target approaches Phase 1 initiation expected in the second half of 2026 NEWTOWN SQUARE, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc.
Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell lines and NSCLC animal models Superior anti-tumor activity of ARR-002 in ovarian cancer models compared to single-target or bivalent approaches with
Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026 Global pivotal Phase 3 first-line PACC mutant NSCLC study for firmonertinib enrollment underway ADC pipeline advancing with first ADC program, ARR-217, in Phase 1 clinical